Get started
Author

Larry Zaiqian Shen

Observed names: L Shen, L. Shen, L. Z. Shen, Larry Shen, Larry Z. Shen
OpenAlex ID: A5113725447
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
2005 · Orville G. Kolterman, Dennis D. Kim, et al. · American Journal of Health-System Pharmacy · 438
Continual Reassessment Method: A Likelihood Approach
1996 · John O'Quigley, Larry Z. Shen · Biometrics · 385
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
2010 · John B. Buse, Daniel J. Drucker, et al. · Diabetes Care · 355
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
2003 · Mark S. Fineman, Thomas A. Bicsak, et al. · Diabetes Care · 351
PDF
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial
2004 · R. E. Ratner, R. Dickey, et al. · Diabetic Medicine · 312
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes
2003 · Priscilla A. Hollander, Philip Levy, et al. · Diabetes Care · 308
PDF
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
2002 · Fred Whitehouse, Davida F. Kruger, et al. · Diabetes Care · 264
Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes
2004 · Mark S. Fineman, Larry Z. Shen, et al. · Diabetes/Metabolism Research and Reviews · 225
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients
2004 · Priscilla Hollander, David G. Maggs, et al. · Obesity Research · 193
PDF
Consistency of continual reassessment method under model misspecification
1996 · L. Shen · Biometrika · 170
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
2011 · Robert Ratner, Jenny Han, et al. · Cardiovascular Diabetology · 153
PDF
Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
2010 · Mark Fineman, Shawn Flanagan, et al. · Clinical Pharmacokinetics · 137
Exenatide Improves Glycemic Control and Reduces Body Weight in Subjects with Type 2 Diabetes: A Dose-Ranging Study
2005 · Terri Poon, Patric Nelson, et al. · Diabetes Technology & Therapeutics · 105
Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
2010 · Louis J. Aronne, Amy E. Halseth, et al. · Obesity · 100
Two-sample Continual Reassessment Method
1999 · John O'Quigley, Larry Z. Shen, et al. · Journal of Biopharmaceutical Statistics · 81
Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis
2003 · D Maggs, L Shen, et al. · Metabolism · 63
Adjunctive Therapy with Pramlintide Lowers HbA1c without Concomitant Weight Gain and Increased Risk of Severe Hypoglycemia in Patients with Type 1 Diabetes Approaching Glycemic Targets
2005 · R. Ratner, F. Whitehouse, et al. · Experimental and Clinical Endocrinology & Diabetes · 62
Addition of pramlintide to insulin therapy lowers HbA 1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets
2003 · P. Hollander, R. Ratner, et al. · Diabetes Obesity and Metabolism · 58
Properties of pramlintide and insulin upon mixing
2005 · Christian Weyer, Mark S. Fineman, et al. · American Journal of Health-System Pharmacy · 46
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
2024 · John A. Hey, Susan Abushakra, et al. · Drugs · 45
Group Sequential Designs for Monitoring Survival Probabilities
1996 · D. Y. Lin, L. Shen, et al. · Biometrics · 41
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
2012 · Börje Darpö, Sager Philip, et al. · British Journal of Clinical Pharmacology · 34
PDF
Steady-State Bioavailability of Estradiol from Two Matrix Transdermal Delivery Systems, Alora and Climara
1998 · Akshay Buch, Larry Shen, et al. · Menopause The Journal of The North American Menopause Society · 17
On Optimal B-Robust Influence Functions in Semiparametric Models
1995 · Larry Z. Shen · The Annals of Statistics · 11
PDF
Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems
1999 · A. B. Buch, L. Z. Shen, et al. · Climacteric · 10
Works count: 40
Citation count: 3,993
H-index: 22
I10-index: 25
Year
Topic
Type